Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	4.89M 4.27M 3.94M 3.63M 6.84M 470M 7M 47.09M 18.52M 230M 18.35M 17.94M 793M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.18M 10.32M 9.51M 17.93M 1.23B 18.33M 123M 48.52M 604M 48.06M 47.01M 2.08B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

20-06-29	Aradigm Corporation Went Out of Business	CI
20-06-12	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
20-04-27	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
20-04-08	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
20-03-30	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
20-03-30	Motion for Asset Sale Approved for Aradigm Corporation	CI
20-03-09	Bidding Procedure Approved for Aradigm Corporation	CI
20-02-20	Motion for Asset Sale Filed by Aradigm Corporation	CI
20-02-20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
19-11-05	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
19-10-30	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
19-10-21	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19-07-19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

20-06-15	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-06-04	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-30	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-04-13	ARADIGM CORP : Other Events (form 8-K)	AQ
20-04-06	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	-.--%	-.--%	-	-	702K
LONZA GROUP AG	-1.29%	-3.11%	-0.35%	+2.64%	49.18B
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+386.06%	+588.97%	39.58B
BEONE MEDICINES AG	-1.70%	+4.46%	+5.93%	+61.54%	34.69B
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+28.41%	-8.52%	34.42B
CELLTRION, INC.	+0.06%	+0.34%	+2.38%	+34.47%	27.11B
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	16.21B
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+72.42%	+116.45%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+14.54%	+15.44%	14.05B
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+18.43%	-31.23%	13.02B
Average	+0.05%	+0.03%	+65.98%	+97.47%	27.07B
Weighted average by Cap.	-0.05%	-0.18%	+79.44%	+122.31%

	2016	2017
Net sales	195K 170K 157K 145K 273K 18.78M 279K 1.88M 739K 9.2M 732K 716K 31.66M	14.46M 12.64M 11.66M 10.75M 20.27M 1.39B 20.72M 139M 54.84M 682M 54.32M 53.13M 2.35B
Net income	-32.94M -28.78M -26.56M -24.48M -46.15M -3.17B -47.17M -317M -125M -1.55B -124M -121M -5.35B	-10.7M -9.36M -8.63M -7.96M -15M -1.03B -15.33M -103M -40.58M -505M -40.2M -39.32M -1.74B
Net Debt	-9.37M -8.19M -7.56M -6.97M -13.13M -903M -13.42M -90.33M -35.53M -442M -35.2M -34.42M -1.52B	7.91M 6.92M 6.38M 5.88M 11.09M 762M 11.33M 76.27M 30M 373M 29.72M 29.07M 1.28B

Aradigm Corporation Stock OTC Bulletin Board

Stocks

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news : Aradigm Corporation

Press Releases: Aradigm Corporation

Other Biotechnology & Medical Research

Financials

Company Profile